Volume 3, Number 3—September 1997
Rapid Increase in the Prevalence of Metronidazole-Resistant Helicobacter pylori in the Netherlands
On This Page
The prevalence of primary metronidazole resistance of Helicobacter pylori was studied in one Dutch hospital from 1993 to 1996 and in two additional Dutch hospitals in 1993 and 1996. All cultures of antral biopsy specimens yielding H. pylori in the study period were evaluated, except those from patients who had received anti-H. pylori treatment; 1,037 H. pylori strains, all from different patients were included. Metronidazole resistance was determined by disk diffusion in 1993 and by Epilipsometer-test in 1994 to 1996. Metronidazole resistance increased from 7% (18/245) in 1993 to 32% (161/509) in 1996. More patients with nonulcer dyspepsia and more non-Western European patients were seen in 1996 than in 1993, but age and sex differences were not observed. A comparable increase in metronidazole resistance was observed in both nonulcer dyspepsia patients and peptic ulcer patients, and the prevalence of metronidazole resistance in Western Europeans increased from 5% in 1993 to 28% in 1996.
Since the first description (1) of Helicobacter pylori and the acceptance of its role in the pathogenesis of peptic ulcer disease (PUD) (2), different regimens to eradicate this microorganism have been used in clinical practice (3). Metronidazole has frequently been used as a component in these treatment regimens. H. pylori resistance to metronidazole has been associated with treatment failure (4-7). Recently, an increase of metronidazole resistance has been reported from different parts of the world (8-13). This retrospective study describes the prevalence of primary metronidazole resistance occurring in H. pylori strains in 1993 and 1996 in three regional hospitals in the northern part of the Netherlands and in 1994-95 in one of these hospitals.
All cultures of antral biopsy specimens yielding growth of H. pylori in the study period were considered for evaluation. Previous anti-H. pylori treatment was the only reason for exclusion. All 1,037 H. pylori strains evaluated were isolated from different patients. Biopsy specimens for culture were taken within 3 cm of the pylorus. Endoscopes and biopsy equipment were thoroughly cleaned with a detergent and disinfected with 2% glutaraldehyde in an automatic washing machine between procedures. Culture was performed as described elsewhere (14).
Susceptibility to metronidazole was determined by disk diffusion in 1993 and the Epilipsometer-test (E-test) in 1994-1996. For these tests, plates were injected with a suspension adjusted to a turbidity approximating that of a McFarland No. 3 standard (15). For disk diffusion, a 5-mg disk (Mast Laboratories, Liverpool, United Kingdom) was used and read after at least 3 days of incubation. Strains with an inhibition zone of 10 mm or more were regarded as susceptible (16). The E-test (AB Biodisk, Solna, Sweden) (17) was performed according to the instructions of the manufacturer and read after at least 3 days. The strains were considered metronidazole resistant when the minimum inhibitory concentration was above 8 g/ml (18).
To test the equivalence of the two methods of susceptibility testing, a prospective study compared the E-test and disk diffusion. In 124 different H. pylori strains, results were concurrent in all but six.
In one of the hospitals (Hospital C), data were available on endoscopic diagnosis, age, and ethnic background of the patients from whom the strains were isolated in 1993 and 1996. In this hospital, it was possible to compare the prevalence of metronidazole resistance in PUD patients with that in nonulcer dyspepsia (NUD) patients and to look at resistance rates in patients of different ethnic backgrounds. Statistical analysis was performed by Fisher's exact test on binomial data and Student's t test on continuous data. Differences were considered significant when p < 0.05.
The number of H. pylori strains isolated in the three hospitals was 245 in 1993 and 509 in 1996. In Hospital C, an additional 137 strains from 1994 and 146 strains from 1995 were studied. Looking at the sex of the study population, we found a male-to-female ratio in 1993 of 1.75:1, in 1994 of 1.36:1, in 1995 of 1:1, and in 1996 of 1.18:1 (the total male-to-female ratio was 1.28:1). The proportion of women in the population examined was higher in 1996 (46%) than in 1993 (36%)(p = 0.02). The prevalence of metronidazole resistance did not differ, however, between men and women. The prevalence of metronidazole resistance increased significantly from 1993 to 1996 in the total sample group (Figure 1) and also among men (from 7% to 30%, p < 0.0001) and women (from 8% to 33%, p < 0.0001).
In Hospital C, the number of strains isolated from PUD patients decreased from 83% to 38%. No significant difference, however, was noted in the prevalence of resistance between NUD patients and PUD patients in 1993 or in 1996 (Figure 2, p < 0.0001). In Hospital C more strains from non-Western European patients were included in 1996 than in 1993 (p = 0.04), and the prevalence of metronidazole resistance was higher in this group than in the total population. Exclusion of this patient group still resulted in an increase in the prevalence among the Western Europeans (p < 0.0001). The mean age of the patients from whom H. pylori strains were isolated in Hospital C was the same in 1993 and 1996 (55 ± 14 [mean ± standard deviation] and 54 ± 16 years, respectively.)
Our study shows a rapidly increasing prevalence of metronidazole resistance in H. pylori in the Netherlands. This increase was observed in all three hospitals included in the study. Our results are consistent with the findings of some investigators (8-13) but not with those of others (19,20). It confirms our own previous experience of increasing resistance in this part of the Netherlands (21,22).
We explored the possibility that the observed rise in metronidazole resistance was due to some known confounding factor such as age, sex, endoscopic diagnosis, or ethnicity. More H. pylori strains were isolated from NUD patients in 1996 than in 1993. In 1996, the proportions of women and foreigners in the examined populations were also higher. In contrast with the results of Ching et al. (23), however, we found that the prevalence of metronidazole resistance in NUD patients and in PUD patients was the same. Furthermore, the prevalence of metronidazole resistance was comparable among men and women in both 1993 and 1996. Exclusion of the non-Western European patients from the analysis still showed a rapid increase in metronidazole resistance. Several authors have suggested that the prevalence of metronidazole resistance is higher in the young and middle-aged (19,20,24-26). In our study population, however, the mean age was the same in 1993 and 1996.
The use of different techniques to measure metronidazole susceptibility could confound the validity of our results (26). However, our prospective study comparing the E-test and disk diffusion, as well as other studies (27,28), show a very high intertest agreement when using the above-stated criteria for metronidazole resistance. We cannot exclude the possibility that other methodologic factors are involved. However, because procedures were standardized and the increase was observed in three different hospitals, each with its own laboratory, we consider this unlikely. Therefore, the observed rapid increase seems real and is relevant for clinical practice (4-7).
Several authors have suggested that the use of imidazoles for other indications, such as gynecologic infections, could account for the resistance increase (6,22-24,28,29). This would also explain the higher prevalence of metronidazole resistance in women that has been observed in several studies (6,19,21,25). Our study, however, did not show a significant difference between men and women or a more apparent increase in women. Moreover, out-of-hospital prescription of metronidazole in the Netherlands increased only slightly from 1989 until 1995 (Figure 3). Some authors have suggested that imidazole-containing regimens themselves could be the cause (25,29,30). However, we consider this unlikely. First, we excluded all strains that were isolated after known anti-H. pylori treatment. We cannot completely exclude the possibility that some of the patients had been treated by their general practitioner without our knowledge. We are, however, confident that this is a rare occurrence because in our region most physicians prescribe their treatment on the basis of endoscopic findings and culture of the biopsy specimens, and we purposely excluded all patients from whom H. pylori was previously isolated. In our region, breath testing is not available for general practitioners, and serologic tests are rarely used. Moreover, imidazole-containing anti-H. pylori regimens are highly effective (3,7), and metronidazole resistance could be induced only in the few H. pylori strains escaping eradication. Finally, as infection is rare during adulthood, it is unlikely that strains rendered resistant in that way spread in the population (31,32). Therefore, although general practitioners may have been treating H. pylori infections more frequently in recent years, it seems unlikely that this could have caused the observed fourfold increase in the prevalence of resistance.
The cause of the rapid increase in metronidazole resistance in H. pylori that we observed can only be a matter of speculation. Apparently, metronidazole-resistant H. pylori strains somehow have a survival advantage, and the increase in metronidazole resistance may be the result of some as yet unknown environmental pressure. Our study suggests that the prevalence of metronidazole resistance in H. pylori is rapidly increasing in the Netherlands. The cause of this increase, however, is still elusive.
- Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;i:1273.
- National Institutes of Health. Consensus conference.Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65–9.
- Van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: review of the world literature. Helicobacter. 1996;1:6–19.
- Van Zwet AA, Thijs JC, Oom JAJ, Hoogeveen J, Düringshoff BL. Failure to eradicate Helicobacter pylori in patients with metronidazole resistant strains. Eur J Gastroenterol Hepatol. 1993;5:185–6.
- Bell GD, Powell K, Burridge SM, Pallecaros A, Jones PH, Gant PW, Experience with "triple" anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pretreatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992;6:427–35.
- Rautelin H, Seppäla K, Renkonen OV, Vainio U, Kosunen TU. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 1992;36:163–6.
- Thijs JC, van Zwet AA, Thijs WJ, Van der Wouden EJ, Kooy A. One week triple therapy with omeprazole, amoxicillin, and tinidazole for Helicobacter pylori infection: the significance of imidazole susceptibility. Aliment Pharmacol Ther. 1997;11:305–9.
- Reddy R, Osato M, Gutiérrez O, Kim JG, Graham DY. Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the U.S [abstract]. Gastroenterology. 1996;110:A238.
- Ling TWK, Cheng AFB, Sung JJY, Yiu PYL, Chung SSC. An increase in Helicobacter pylori strains resistant to metronidazole: a five year study. Helicobacter. 1996;1:57–61.
- Xia HX, Keane CT, O'Morain CA. A 5-year survey of metronidazole and claritromycin resistance in clinical isolates of Helicobacter pylori [abstract]. Gut. 1996;39:A6.
- Lopez-Brea M, Martinez MJ, Domingo D, Sanchez Romero I, Sanz JC, Alarcon T. Evolution of the resistance to several antibiotics in Helicobacter pylori over a four year period [abstract]. Gut. 1995;37:A97.
- Teo EK, Fock KM, Ng TM, Chia SC, Khor CJL, Tan AL, Primary and secondary metronidazole resistant Helicobacter pylori in an urban asian population [abstract]. Gut. 1996;39:A23–4.
- Weissfeld AS, Simmons DE, Vance PH, Trevino E, Kidd S, Greski-Rose P. In vitro susceptibility of pre-treatment isolates of Helicobacter pylori from two multicenter United States clinical trials [abstract]. Gastroenterology. 1996;110:A295.
- Van Zwet AA, Thijs JC, Roosendaal R, Kuipers EJ, Pena S, de Graaff J. Practical diagnosis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1996;8:501–7.
- Berger SA, Gorea A, Moskowitz M, Santo M, Gilat T. Effect of inoculum size on antimicrobial susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1993;12:782–3.
- DeCross AJ, Marshall BJ, McCallum RW, Hoffman SR, Barrett LJ, Guerrant RL. Metronidazole susceptibility testing for H. pylori: comparison of disk, broth and agar dilution methods and their clinical relevance. J Clin Microbiol. 1993;31:1971–4.
- Graham DY, Börsch GM. The who's and when's of therapy for Helicobacter pylori [editorial]. Am J Gastroenterol. 1990;85:1552–5.
- National Committee for Clinical Laboratory Standards. Standard MF-A. Villanova, PA: National Committee for Clinical Laboratory Standards; 1990.
- Karim QN, Logan RPH. Helicobacter pylori (H. pylori) antimicrobial resistance in the UK [abstract]. Gut. 1996;39:A15.
- De Koster E, Cozzoli A, Jonas C, Ntounda R, Butzler JP, Deltenre M. Six years resistance of Helicobacter pylori to macrolides and imidazoles [abstract]. Gut. 1996;39:A5.
- Thijs JC, Van Zwet AA, Oey HB. Efficacy and side effects of a triple drug regimen for eradication of Helicobacter pylori. Scand J Gastroenterol. 1993;28:934–8.
- Van Zwet AA, De Boer WA, Schneeberger PM, Weel J, Jansz AR, Thijs JC. Prevalence of primary Helicobacter pylori resistance to metronidazole and claritromycin in The Netherlands. Eur J Clin Microbiol Infect Dis. 1996;15:861–4.
- Ching CK, Leung KP, Yung RWH, Lam SK, Wong BC, Lai KC, Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut. 1996;38:675–8.
- Banatvala N, Davies GR, Abdi Y, Clements L, Rampton DS, Hardie JM, High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut. 1994;35:1562–6.
- Glupczynski Y, Burette A, De Koster E, Nyst JF, Deltenre M, Cadranel S, Metronidazole resistance in Helicobacter pylori [letter]. Lancet. 1990;335:976–7.
- European Study Group on Antibiotic Susceptibility of. Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1992;11:777–81.
- Hirschl AM, Hirschl MM, Rotter ML. Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother. 1993;32:45–9.
- Midolo PD, Turnidge J, Lambert JR, Bell JM. Validation of a modified Kirby-Bauer disk diffusion method for metronidazole susceptibility testing of Helicobacter Pylori. Diagn Microbiol Infect Dis. 1995;21:135–40.
- Becx MCJM, Janssen AJHM, Clasener HAL, de Koning RW. Metronidazole-resistant Helicobacter pylori [letter]. Lancet. 1990;335:539–40.
- Weil J, Bell GD, Powell K, Jobson R, Trowell JE, Gant P, Helicobacter pylori and metronidazole resistance [letter]. Lancet. 1990;336:1445.
- Walt RP. Metronidazole resistant H. pylori of questionable clinical importance. Lancet. 1996;348:489–90.
- Megraud F. Epidemiology of Helicobacter pylori infection: where are we in 1995? Eur J Gastroenterol Hepatol. 1995;7:292–5.
Suggested citation: van der Wouden EJ, van Zwet AA, Thijs JC, Vosmaer GDC, Oom JAJ, de Jong A, et al. Rapid Increase in the Prevalence of Metronidazole-Resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis [serial on the Internet]. 1997, Sep [date cited]. Available from http://wwwnc.cdc.gov/eid/article/3/3/97-0320
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: December 21, 2010
- Page last updated: December 21, 2010
- Page last reviewed: December 21, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)